Funding profile · Consumer telehealth

Phoenix

One disclosed round, reported as a single number mixing equity and venture debt, in a private Canadian corporation that files no readable securities notice. The public paper trail is a federal registry entry and two reporters’ notebooks.

Data as of September 24, 2026. Company-reported figures are labeled. All amounts are Canadian dollars unless stated.

Rounds at a glance

What the filings show

Reading the filings

1. The headline number is two instruments wearing one label.The March 13, 2025 release says CAD 50 million and names Valspring Capital as lead, Y Combinator as returning, and CIBC Innovation Banking for venture debt. BetaKit reports the equity portion was all primary and that Bache called the round “mostly equity” but declined the split and the valuation. The equity raised is therefore below $50 million, and the number carries no implied valuation.
2. The totals reconcile.BetaKit puts cumulative funding at $55 million in March 2025. The Local reports about $5 million raised before. $55 million minus $50 million is $5 million, so the two independent figures agree and imply no hidden earlier round.
3. Two board seats arrived with the cheque.Valspring managing partner Yumin Choi and senior principal Amanda Zajac joined the board as part of the round. For a company still registered as having 50 or fewer shareholders, that is meaningful concentration of investor voice.
4. The corporate record shows one lapse, cured.Corporations Canada logged “Active – Dissolution Pending (Non-compliance)” on March 24, 2023, the same day the 2022 annual return was filed. The 2025 annual meeting is on record, so filing discipline is current.
5. Unit economics sit in the medication, not the visit.BetaKit reports $40 per online visit, physicians paid whether or not they prescribe, and revenue generated from medication sales. Gross margin therefore depends on conversion to a filled prescription and on refills. That is the structure critics cite, and it is why the May 2026 price moves on semaglutide and Ozempic, both from $124.99, are strategy rather than charity.
6. A manufacturer is now inside the checkout.The May 29, 2026 release states the Novo Nordisk savings card rebate is applied automatically at checkout for eligible Ozempic prescriptions, for out-of-pocket patients outside Quebec. That is a direct commercial link between a brand manufacturer and the platform where the prescribing decision is recorded.

Commercial signals

What to watch

• A Series B, or any disclosure of the equity and debt split inside the 2025 number.
• Quebec entry, which would enlarge the addressable market by roughly a fifth of the country.
• Any first disclosure of patient counts, revenue or retention, none of which has been published.
• Whether Raven is financed and reported separately or stays inside the same corporation.
• Further manufacturer rebate arrangements of the Novo Nordisk type, and how they are disclosed to patients.

The Phoenix story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Legacy: Shared investor: Bain Capital Ventures. A mail-in kit that tests sperm, and then freezes it, without a clinic visit
• TrueClaim: Shared investor: Bain Capital Ventures. A Y Combinator backed third party administrator trying to run self funded employer health plans on modern software
• NimbleRx: Also in Consumer Health and Wellness. Nimble began as a licensed dispensing pharmacy with its own stores, shut them in early 2019, and rebuilt itself as the software layer sold to the independent pharmacies
• TAXA Biotechnologies: Also in Consumer Health and Wellness. The company behind the first synthetic biology crowdfunding campaign

Sources

1. Public recordPhoenix Digital Health Inc., federal corporation 11618938Corporations Canada, via open government data · accessed Sep 24, 2026
2. Public recordForm D search and Form D mentions, no filing for the companySEC EDGAR · Sep 24, 2026
3. Public recordCanada becomes the first G7 country to approve a generic version of semaglutideHealth Canada · Apr 28, 2026
4. IndependentPhoenix secures equity from Valspring, venture debt from CIBC for prescription drug serviceBetaKit, Josh Scott · Mar 13, 2025
5. IndependentInside the Booming Industry Selling Lifestyle Drugs OnlineThe Local, Inori Roy · Feb 3, 2026
6. CompanyPhoenix Announces $50 Million Investment Round Led by Valspring CapitalBusiness Wire · Mar 13, 2025
7. CompanyPhoenix and Raven Become First Canadian Telehealth Platforms to Offer Generic Semaglutide Direct to PatientsBusiness Wire · May 20, 2026
8. CompanyPhoenix and Raven Offer Eligible Canadians Ozempic at the Same Price as Generic SemaglutideBusiness Wire, via BNN Bloomberg · May 29, 2026
9. PartnerTrulioo Partners With Phoenix Digital Health to Strengthen Patient Trust and Access to Virtual Care in CanadaBusiness Wire · Apr 14, 2026
10. CompanyPhoenix terms of service, FAQ and locations pagesphoenix.ca · accessed Sep 2026

Compiled from Corporations Canada, SEC EDGAR, Health Canada and provincial regulator records and published reports as of September 24, 2026. Phoenix Digital Health Inc. is a private Canadian corporation filing no public financial statements; figures here come from company releases and independent reporting, labeled as such. Healthcare Venture Capital Fund holds no position in Phoenix Digital Health Inc. This page is not an offer to sell or a recommendation to buy any security.